Hidden inherited genes in endometrial cancer: a new study investigates

NCT ID NCT07066969

Not yet recruiting Knowledge-focused Sponsor: European Institute of Oncology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test 20 people with endometrial cancer who also have a BRCA mutation in their tumor. Researchers will look for inherited (germline) gene changes using a blood test. The goal is to better understand genetic risks in this type of cancer. No treatment is given; it is purely an observational study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sophia DDM germline panel (genetic test)
What this could lead to: If successful, this could help identify inherited genetic risks in endometrial cancer patients, potentially guiding family screening and personalized prevention.
What could go wrong: This is a very small, early-stage observational study (20 participants) with no treatment being tested. It may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER

Contacts and locations

Locations

European Institute of Oncology

Milan, 20141, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.